Cognitive and behavioral heterogeneity in Alzheimer's disease: Seeking the neurobiological basis

Neurobiology of Aging

Volumn 21, Issue 6, 2000, Pages 845-861

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Animal models; Behavior; Cognition; Imaging; Treatment

Indexed keywords

PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; ANIMAL MODEL; APHASIA; BEHAVIOR; BRAIN REGION; COGNITION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEPRESSION; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; IMAGING; MENTAL TEST; NEUROPATHOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSGENIC MOUSE;

EID: 0033637008     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(00)00183-4     Document Type: Note

References (176)

1. Pathology, neurobiology, and animal models of Alzheimer's disease
2. Neurotransmitters and neuropeptides
3. The metabolism of apolipoprotein E and the Alzheimer's diseases
4. Neuroimmune mechanisms in the pathogenesis of Alzheimer's disease
5. Clinical diagnosis of Alzheimer's disease; report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
6. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease
7. Generative associative naming in dementia of Alzheimer's type
8. The use of phonemic cueing with Alzheimer's disease patients
9. Aphasia in dementia of the Alzheimer type
10. Language disintegration in dementia; effects of etiology and severity
11. The dissolution of language in Alzheimer's disease
12. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease
13. Wechsler Adult Intelligence Scale Performance
14. Alzheimer's disease; focal cortical changes shown by positron emission tomography
15. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type
16. Visual variant of Alzheimer disease; distinctive neuropsychological features
17. Spatial disorientation in Alzheimer's disease
18. Posterior cortical atrophy
19. Simultanagnosia as the initial sign of degenerative dementia
20. The visual variant of Alzheimer's disease; a clinicopathologic case study
21. Posterior cortical atrophy; unique features
22. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease; clinical implications
23. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type
24. Clinical and pathological evidence for a frontal variant of Alzheimer disease
25. Executive dysfunction in Alzheimer's disease; association with neuropsychiatric symptoms and functional impairment
26. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB); report of the consortium on DLB international workshop
27. Pathological correlates of extrapyramidal signs in Alzheimer's disease
28. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with Parkinsonism
29. Cognitive decline in patients with Alzheimer's disease; differences in patients with and without extrapyramidal signs
30. Patterns of neuropsychological performance in Alzheimer's disease patients with and without extrapyramidal signs
31. The Global Deterioration Scale for assessment of primary degenerative dementia
32. A new clinical scale for the staging of dementia
33. The rate of progression of Alzheimer's disease in the later stages; evidence from the severe impairment battery
34. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease
35. Cholinergic markers in elderly patients with early signs of Alzheimer disease
36. Psychiatric phenomena in Alzheimer's disease. I; disorders of thought content
37. Psychiatric phenomena in Alzheimer's disease. II; disorders of perception
38. Psychiatric phenomena in Alzheimer's disease. III; disorders of mood
39. Psychiatric phenomena in Alzheimer's disease. IV; disorders of behavior
40. Psychotic symptoms and physically aggressive behavior in Alzheimer's disease
41. The spectrum of behavioral changes in Alzheimer's disease
42. Psychiatric symptoms associated with Alzheimer's disease
43. The psychiatric symptoms of Alzheimer's disease
44. Troublesome and disruptive behaviors in dementia; relationships to diagnosis and disease severity
45. Assessment of behavioral problems in dementia; the revised memory and behavior problems checklist
46. The evolution of psychiatric symptoms in Alzheimer's disease; a natural history study
47. Psychopathology of very mild dementia of the Alzheimer type
48. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease
49. Noncognitive disturbances in Alzheimer's disease; frequency, longitudinal course, and relationship to cognitive symptoms
50. Psychotic symptoms in Alzheimer's disease
51. Delusional misidentification of persons in dementia
52. The nature of psychotic symptoms in senile dementia of the Alzheimer type
53. Psychosis as the first manifestation of degenerative dementia
54. Factors associated with psychotic symptoms in Alzheimer's disease
55. Alteration of regional cerebral glucose utilization with delusions in Alzheimer's disease
56. Frontal lobe hypometabolism and depression in Alzheimer's disease
57. Age and psychosis in degenerative dementia
58. Neuropsychiatric and neuropsychological correlates of delusions in Alzheimer's disease
59. Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease
60. Cognitive deficits of patients with Alzheimer's disease with and without delusions
61. Delusions in dementia syndromes; investigation of behavioral and neuropsychological correlates
62. Delusions and patterns of cognitive impairment in Alzheimer's disease
63. Associations of psychotic symptoms in dementia sufferers
64. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease
65. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type
66. Psychotic features and the course of Alzheimer's disease; relationship to cognitive, electroencephalographic and computerized tomography findings
67. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease
68. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease
69. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease; prospective analyses from the Predictors Study
70. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease
71. Abnormal brain glucose metabolism in the delusional misidentification syndromes; a positron emission tomography study in Alzheimer's disease
72. SPECT findings on psychosis in Alzheimer's disease
73. A SPECT study of delusions in Alzheimer's disease
74. Psychometric, and SPECT studies in Alzheimer's disease with and without delusions
75. Neuropathologic and neurochemical correlates of psychosis in primary dementia
76. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease
77. Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type
78. Mapping histology to metabolism; coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease
79. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease
80. Psychosis and physical aggression in probable Alzheimer's disease
81. Physical aggression and associated factors in probable Alzheimer disease
82. Prevalence and correlates of aggressive behavior in Alzheimer's disease
83. Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia
84. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease
85. Depressive symptoms in Alzheimer disease; assessment and determinants
86. Depressive symptoms in Alzheimer's disease and multi-infarct dementia
87. Dementia of the Alzheimer's type and depression
88. Depression, and Alzheimer's disease
89. Prevalence of depression in Alzheimer's disease and validity of research diagnostic criteria
90. A questionaire investigation of anxiety and depression in early dementia
91. Prevalence and incidence of major depression in Alzheimer's disease
92. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community
93. Association between family history of affective disorder and the depressive syndrome of Alzheimer's disease
94. Confirmation of an association between family history of affective disorder and the depressive syndrome in Alzheimer's disease
95. Clinical symptoms associated with age at onset in Alzheimer's disease
96. Depression, cognition, and functional ability in patients with Alzheimer's disease
97. Major depression in a population of demented and nondemented older people; prevalence and correlates
98. Major and minor depression in Alzheimer's disease; prevalence and impact
99. Depression, delusions, and hallucinations in Alzheimer's disease; no relationship to apolipoprotein E genotype
100. Effect of depression on dementia presentation; qualitative assessment with the Qualitative Evaluation of Dementia (QED)
101. Psychiatric correlates of MR deep white matter lesions in probable Alzheimer's disease
102. The apolipoprotein E e4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alheimer's disease
103. Alterations in cathecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression
104. Clinical and neuropathological correlates of depression in Alzheimer's disease
105. The neuropathology of aminergic nuclei in Alzheimer's disease
106. Major depression in primary dementia; clinical and neuropathologic correlates
107. Neurochemical correlates of major depression in primary dementia
108. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease; correlations with depression and neuroleptic medication
109. Personality alterations in dementia of the Alzheimer type
110. Personality alterations in dementia of the Alzheimer type; a three-year follow-up study
111. Personailty changes in Alzheimer's disease
112. Primary caregivers' descriptions of Alzheimer patients' personality traits; temporal stability and sensitivity to change
113. The progression of personality changes in senile dementia of the Alzheimer's type
114. The Neuropsychiatric Inventory; comprehensive assessment of psychopathology in dementia
115. Apathy is not depression
116. Cerebral blood flow correlates of apathy in Alzheimer disease
117. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease; relationship to dementia severity
118. Clinical and neuropsychological characterisitcs in familial and sporadic Alzheimer's disease; relation to apolipoprotein E polymorphism
119. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects
120. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease
121. No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease
122. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+
123. Psychotic symptoms and apolipoprotein E genotypes in an elderly population
124. Apolipoprotein E; depressive illness, depressive symptoms, and Alzheimer's disease
125. A twin study of late-onset depression and apolipoprotein E e4 as risk factors for Alzheimer's disease
126. The association between Apo E genotype and depressive symptoms in elderly African-American subjects
127. Apolipoprotein E genotype and noncognitive symptoms of Alzheimer's disease
128. 5-HT(2A) and 5-HT(2C) receptor polymorphisms and psychopathology in late onset Alzheimer's disease
129. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region
130. Association between serotonin transporter gene polymorphism and anxiety-related traits
131. Imaging receptors in psychiatry
132. PET studies in mood disorders
133. Pharmacokinetic studies using positron emission tomography
134. The advantage of using positron emission tomography in drug research
135. Imaging of neurotransmitter receptors in the living human brain
136. 123I]-IBZM
137. 123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease
138. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects
139. The effect of carbamazepine on cerebral glucose metabolism
140. 2 receptor occupancy with low-dose haloperidol treatment; a PET study
141. Binding of antipsychotic drugs to cortical 5-HT(2A) receptors; a PET study of cholorpromazine, clozapine, and amisulpride in schizophrenic patients
142. Selective pharmacologic activation of limbic structures in human volunteers; a positron emission tomography study
143. Experimental and clinical methods in the development of anti-Alzheimer's drugs
144. Mechanisms of directed attention in the human extrastriate cortex as revealed by functional MRI
145. Failure at task-specific regional brain activation; new conceptualization of a disease entity
146. Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded 'Stress Test' during PET
147. Functional anatomy of human procedural learning determined with regional cerebral blood flow and PET
148. Remembering the past; two facets of episodic memory explored with positron emission tomography
149. Distribution of cortical neural networks involved in word comprehension and word retrieval
150. Selective memory loss following nucleus basalis lesions; long term behavioral recovery despite persistent cholinergic deficiencies
151. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat
152. Loss of cholinergic neurons in the rat neocortex produces deficits in passive avoidance learning
153. Basal forebrain-lesioned monkeys are severely impaired in tasks of association and recognition memory
154. Lesions of cholinergic forebrain nuclei; changes in avoidance behavior and scopolamine actions
155. Basal forebrain lesions in monkeys disrupt attention but not learning and memory
156. Human nerve growth factor improves spatial memory in aged but not in young rats
157. Changes in cortical EEG and cholinergic function in response to NGF in rats with nucleus basalis lesions
158. Intraventricular nerve growth factor administration prevents lesion-induced loss of septal cholinergic neurons in aging rats
159. Long-term protective effects of human recombinant nerve growth factor and monosialoganglioside GM1 treatment on primate nucleus basalis cholinergic neurons after neocortical infarction
160. Grafting genetically modified cells to the damaged brain; restorative effects of the NGF expression
161. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates
162. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain
163. Rodent models of Alzheimer's disease; rat AB infusion approaches to amyloid deposits
164. Genetic neurodegenerative diseases; the human illness and transgenic models
165. Apolipoprotein E, a gene with complex biological interactions in the aging brain
166. Lack of apolipoprotein E dramatically reduces amyloid B-peptide deposition
167. Behavioral screening for cognition enhancers; from indiscriminate to valid testing: part I
168. Behavioral screening for cognition enhancers; from indiscriminate to valid testing: part II
169. Animal models of psychiatric disorders
170. Animal models of depression and schizohrenia
171. Animal models of depression
172. Genetic variation in susceptibility to endocrine disruption by estrogen in mice
173. Serotonergic mediation of DRL 72s behavior; receptor subtype involvement in a behavioral screen for antidepressant drugs
174. Augmentation of antidepressant pharmacotherapy; a preclinical approach using the Mouse Forced Swimming Test